WallStreetZenWallStreetZen

NYSEMKT: AIM
Aim Immunotech Inc Stock

$0.40+0.01 (+2.56%)
Updated May 17, 2024
AIM Price
$0.40
Fair Value Price
N/A
Market Cap
$20.67M
52 Week Low
$0.32
52 Week High
$0.75
P/E
-0.63x
P/B
4.28x
P/S
120.7x
PEG
N/A
Dividend Yield
N/A
Revenue
$193.00k
Earnings
-$31.12M
Gross Margin
74.1%
Operating Margin
-16,086.01%
Profit Margin
-16,123.3%
Debt to Equity
2.36
Operating Cash Flow
-$22M
Beta
-0.31
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

AIM Overview

AIM ImmunoTech, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. The company is headquartered in Ocala, Florida and currently employs 31 full-time employees. The firm is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The firm's segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The firm's products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen is a drug undergoing clinical development for the treatment of Chronic Fatigue Syndrome (CFS). Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) is a low-dose, oral liquid formulation of natural alpha interferon. Alferon LDO is a liquid natural interferon for oral administration.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AIM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

AIM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AIM is good value based on its book value relative to its share price (4.28x), compared to the US Biotechnology industry average (6.01x)
P/B vs Industry Valuation
AIM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more AIM due diligence checks available for Premium users.

Be the first to know about important AIM news, forecast changes, insider trades & much more!

Valuation

AIM price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.63x
Industry
8.47x
Market
30.97x

AIM price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
4.28x
Industry
6.01x
AIM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

AIM's financial health

Profit margin

Revenue
$40.0k
Net Income
-$5.8M
Profit Margin
-14,542.5%
AIM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AIM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$16.2M
Liabilities
$11.4M
Debt to equity
2.36
AIM's short-term assets ($11.31M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AIM's short-term assets ($11.31M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AIM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AIM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$4.8M
Investing
-$158.0k
Financing
$2.8M
AIM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

AIM vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
AIM$20.67M+3.33%-0.63x4.28x
LUMO$20.62M-3.42%-0.55x1.18x
SLGL$20.89M+1.49%-0.74x0.54x
VINC$20.41M-4.03%-0.39x-32.81x
MEIP$20.99M+7.51%0.80x0.41x

Aim Immunotech Stock FAQ

What is Aim Immunotech's quote symbol?

(NYSEMKT: AIM) Aim Immunotech trades on the NYSEMKT under the ticker symbol AIM. Aim Immunotech stock quotes can also be displayed as NYSEMKT: AIM.

If you're new to stock investing, here's how to buy Aim Immunotech stock.

What is the 52 week high and low for Aim Immunotech (NYSEMKT: AIM)?

(NYSEMKT: AIM) Aim Immunotech's 52-week high was $0.75, and its 52-week low was $0.32. It is currently -46.19% from its 52-week high and 25.94% from its 52-week low.

How much is Aim Immunotech stock worth today?

(NYSEMKT: AIM) Aim Immunotech currently has 51,281,437 outstanding shares. With Aim Immunotech stock trading at $0.40 per share, the total value of Aim Immunotech stock (market capitalization) is $20.67M.

Aim Immunotech stock was originally listed at a price of $2,145.26 in Dec 31, 1997. If you had invested in Aim Immunotech stock at $2,145.26, your return over the last 26 years would have been -99.98%, for an annualized return of -28.11% (not including any dividends or dividend reinvestments).

How much is Aim Immunotech's stock price per share?

(NYSEMKT: AIM) Aim Immunotech stock price per share is $0.40 today (as of May 17, 2024).

What is Aim Immunotech's Market Cap?

(NYSEMKT: AIM) Aim Immunotech's market cap is $20.67M, as of May 18, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Aim Immunotech's market cap is calculated by multiplying AIM's current stock price of $0.40 by AIM's total outstanding shares of 51,281,437.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.